Sökning: id:"swepub:oai:DiVA.org:uu-113890" >
A randomized study ...
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer
-
Qvortrup, Camilla (författare)
-
Jensen, B. V. (författare)
-
Fokstuen, T. (författare)
-
visa fler...
-
Nielsen, S. E. (författare)
-
Keldsen, N. (författare)
-
- Glimelius, Bengt (författare)
- Karolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
-
Bjerregaard, B. (författare)
-
Mejer, J. (författare)
-
Larsen, F. O. (författare)
-
Pfeiffer, P. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2010
- 2010
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 21:1, s. 87-91
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Chronotherapy is one of the several approaches to increase efficacy and reduce toxicity of chemotherapy. In a phase II study in the second-line in patients with metastatic colorectal cancer (mCRC), we found that chronomodulated XELOX (XELOX(30Chron)) was a well-tolerated regimen with potentially reduced toxicity. PATIENTS AND METHODS: One hundred and forty-one patients with unresectable mCRC were enrolled in a randomized study comparing standard XELOX (XELOX(30)), arm A, and XELOX(30Chron), arm B-both with short-time infusion of oxaliplatin-with the primary aim of reducing overall toxicity. RESULTS: Overall toxicity grade 2-4 was 90% versus 85%, P = 0.47 and grade 3-4 was 31% versus 37%, P = 0.6 in arm A and B, respectively. We found no significant differences in median overall survival (17.6 versus 15.5 months; P = 0.068) and median progression-free survival (8.9 versus 8.8 months; P = 0.7). The incidence of grade 3 neuropathy was 16% in arm A and 19% in arm B (P = 0.7) after a cumulative dose of oxaliplatin of 1000 mg/m(2). CONCLUSION: XELOX(30Chron) does not reduce toxicity or improve efficacy. A 30-min infusion of oxaliplatin is safe and does not increase the severity of chronic neuropathy.
Nyckelord
- capecitabine
- chronotherapy
- colorectal cancer
- oxaliplatin
- randomized
- short-time infusion
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Qvortrup, Camill ...
-
Jensen, B. V.
-
Fokstuen, T.
-
Nielsen, S. E.
-
Keldsen, N.
-
Glimelius, Bengt
-
visa fler...
-
Bjerregaard, B.
-
Mejer, J.
-
Larsen, F. O.
-
Pfeiffer, P.
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet